Hey, it's Ryan. This is the final episode of trillion dollar shot. Our special series about a new class of drugs like Ozempik, which people are using to lose weight.

The first three episodes are already in your feed, and you can find a link to them in the show notes. So Brad, I know you've covered tech for a long time.

Five years.

Mm-hmm.

So let me ask you, when you think of the term disruptors what comes to mind.

Oof. I live near Silicon Valley and I have to hear everyone talk about disrupting everything.

It's sometimes true and sometimes a stretch, really, right?

Right.

I bet it's kind of become like a cliche out in Silicon Valley right everyone's disrupting everything yes

yes the scooter people are going to change transportation forever because they

have an electric scooter on the road for example no offense to the scooter people.

Yes, yes.

But you know, I've been thinking about these new weight loss medications, often referred to

as GLP1s.

And there is a world in which we could say they're disruptors.

It's one of those cases where it actually applies, like it fits very, very well.

Right, because these drugs might be one of the most disruptive advances in science and health in decades.

Yes.

But maybe the biggest company in this booming market right now is the

pharma giant Eli Lilly and it's not based in Silicon Valley. It's based in

Indiana. I talked to the CEO Dave Ricks.

Indiana is known for only a few things and two of them are universities and Eli Lilly.

...